The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of weekly scheduled irinotecan and capecitabine treatment in advanced colorectal cancer patients.
Wenhua Li
No relevant relationships to disclose
Jin Li
No relevant relationships to disclose
Jianming Xu
No relevant relationships to disclose
Lin Shen
No relevant relationships to disclose
Tianshu Liu
No relevant relationships to disclose
Wei jian Guo
No relevant relationships to disclose
Wen Zhang
No relevant relationships to disclose